Long-term safety registry for EB treatment
Part of Genetic & congenital, Skin clinical trials.
This study follows patients who have already received a gene therapy treatment called prademagene zamikeracel for a severe skin condition called recessive dystrophic epidermolysis bullosa (RDEB). The goal is to track long-term safety and health outcomes after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already received treatment with prademagene zamikeracel for RDEB in real-world clinical care.
- You or your guardian must be willing to sign a consent form agreeing to participate.
- You must be able to follow the study's procedures as determined by the study doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called efgartigimod (VYVGART) to see if it can lower harmful antibodies in people with certain blistering skin diseases—dystrophic epidermolysis bullosa (DEB) and epidermolysis bullosa acquisita (EBA). If you have these antibodies, this treatment might help reduce blistering.
This trial tests a new skin graft made with your own cells that have been genetically modified to produce a missing protein (collagen 7). It's for people with RDEB, a severe blistering condition, and aims to see if the graft can heal wounds safely.
This study follows people who previously received a gene therapy from Krystal Biotech to better understand long-term safety and outcomes. If you already had their gene therapy before and you can keep follow-up appointments, you may be able to join.
This study tests an experimental eye drop (KB803) to see if it can reduce painful scrapes on the surface of the eye in people with dystrophic epidermolysis bullosa. You would be randomly assigned to receive either the study drops or a placebo (an inactive drop) for several months.
This study looks at long-term outcomes for people with recessive dystrophic epidermolysis bullosa (RDEB) who were previously treated with EB-101. It may help doctors understand how the treatment affects patients over time.
This study looks at the medical features and needs of people who have recessive dystrophic epidermolysis bullosa (RDEB). It may help doctors better understand the condition and plan better care.
Hear when a new Recessive Dystrophic Epidermolysis Bullosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.